03/08/2026 Akebia Therapeutics announced the initiation of a Phase 2 basket trial evaluating ebribafusp in rare complement-mediated kidney disease Akebia Therapeutics announced the initiation of a Phase 2 basket trial evaluating ebribafusp in rare complement-mediated kidney disease (Ref) Akebia Therapeutics announced the initiation of a Phase 2/ NCT06419205 basket trial evaluating the safety, efficacy and pharmacokinetics of ebribafusp (AKB-097 and ADX-097; anti-C3d factor H